Protecting-Group-Free Synthesis of Meridianin A–G and Derivatives and Its Antibiofilm Evaluation
作者:Huidan Geng、Fei Chen、Yonglong Zhao、Bing Guo、Lei Tang、Yuan-Yong Yang
DOI:10.1021/acs.joc.2c02837
日期:2023.3.17
Herein, a protecting-group-free protocol was developed to realize a time and step economy diversification of the Meridianin alkaloid. A broad range of substituents are tolerated to deliver the products in moderate to high yields, and the first synthesis of Meridianin B was achieved. The simplicity of this protocol enables the rapid construction of a Meridianin derivative library for antibiofilm evaluation
在此,开发了一种无保护基团的方案,以实现 Meridianin 生物碱的时间和步骤经济多样化。广泛的取代基可以以中等到高的产率提供产品,并且实现了 Meridianin B 的首次合成。该协议的简单性使得能够快速构建用于抗生物膜评估的 Meridianin 衍生物库。初步结果表明,经络宁衍生物能够协同抑制鲍曼不动杆菌生物膜并降低抗生素 MIC。
Synthesis of the indole alkaloids meridianins from the tunicate Aplidium meridianum
作者:Pilar M Fresneda、Pedro Molina、Juan A Bleda
DOI:10.1016/s0040-4020(01)00102-8
日期:2001.3
The marine natural products meridianins A and C-E have been synthesized for the first time starting from the appropriate N-tosyl-3-acetylindole. A facile two-step conversion of N-tosyl-3-acetylindoles to the corresponding meridianins by treatment with dimethylformamide dimethylacetal and further cyclization of the resulting enaminone with aminoguanidine is described. This method has also been applied for the preparation of the 3-[(2-amino)pyrimidin-4-yl]-7-azaindole. (C) 2001 Elsevier Science Ltd. All rights reserved.
METHODS FOR THE TREATMENT OF AMYLOID-BETA RELATED DISORDERS AND COMPOSITIONS THEREFOR
申请人:The Rockefeller University
公开号:EP2077838B1
公开(公告)日:2013-04-03
METHODS FOR THE TREATMENT OF A RELATED DISORDERS AND COMPOSITIONS THEREFOR
申请人:The Rockefeller University
公开号:EP2077838A2
公开(公告)日:2009-07-15
METHODS FOR THE TREATMENT OF A-BETA RELATED DISORDERS AND COMPOSITIONS THEREFOR
申请人:Flajolet Marc
公开号:US20100143361A1
公开(公告)日:2010-06-10
The invention provides methods for treating Aβ peptide related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 modulator to a patient in need thereof.